RxDoctor Payments Data

Brian McKee, MD

Ophthalmology · Newport News, VANPI 1407841133

Payments from drug & device makers

$3,273in general payments, 2019–2025

Across 103 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$734
  • Bausch & Lomb Americas Inc.$680
  • Alcon$376
  • Aerie Pharmaceuticals, Inc.$332
  • Tarsus Pharmaceuticals, Inc.$280
  • Novartis$169
  • plus $702 from 12 others

What the payments were for

  • Food & beverage$3,273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,273 in reported general payments places this provider in the 75th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$382,014
Medicare patients
902
Services billed
3,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$36,924
LumiganBimatoprost42$30,575
RocklatanNetarsudil Mesylat/Latanoprost44$17,318
XiidraLifitegrast14$12,391
SimbrinzaBrinzolamide/Brimonidine Tart41$9,237
VyzultaLatanoprostene Bunod18$8,814
CombiganBrimonidine Tartrate/Timolol18$7,265
Travoprost13$3,724
Timolol Maleate45$3,601
Ketorolac Tromethamine92$1,943
Prednisolone Acetate84$1,851
Brimonidine Tartrate39$887
Latanoprost138$854
Ofloxacin51$589
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha36$469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$734$74,76489 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$680$21,20432 claims
Aerie Pharmaceuticals, Inc.Rocklatan$332$17,31844 claims
AlconSimbrinza$376$9,23741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →